RRM2 and small cell lung carcinoma: Taken together, the outcomes of the gene enrichment study, ChIP-assay, and pharmacological inhibition of CXCR4 or FOXM1, or genetic knockdown of FOXM1 establish that miR-1 modulates the CXCR4/FOXM1/RRM2 axis in SCLC cells (Fig. 7G).